GS 1427
Alternative Names: GS-1427; α4β7 inhibitor - Gilead SciencesLatest Information Update: 12 Apr 2024
At a glance
- Originator Gilead Sciences
- Class Anti-inflammatories
- Mechanism of Action Alpha4beta7 integrin antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Ulcerative colitis
- Phase I Inflammatory bowel diseases
Most Recent Events
- 27 Mar 2024 Phase-II clinical trials in Ulcerative colitis (In adults, In the elderly, Combination therapy) in USA (PO) (NCT06290934)
- 27 Mar 2024 Phase-II clinical trials in Ulcerative colitis (In adults, In the elderly, Monotherapy) in USA (PO) (NCT06290934)
- 04 Mar 2024 Gilead Sciences plans a phase II trial for Ulcerative Colitis (In adults, In the elderly, Monotherapy, Combination-therapy) in March 2024 (PO) (NCT06290934)